<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715570</url>
  </required_header>
  <id_info>
    <org_study_id>PC_ASP_001</org_study_id>
    <secondary_id>2015-003327-64</secondary_id>
    <nct_id>NCT02715570</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945</brief_title>
  <official_title>A Randomised, Single-blind, Placebo-controlled, Study to Assess the Safety and Tolerability of Single Escalating and Repeat, Inhaled Doses of PC945 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC945 in Subjects With Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmocide Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmocide Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PC945 is a new medicine being developed for treatment of fungal lung diseases. The main
      purpose of this study is to investigate the safety, tolerability and pharmacokinetics of
      single and repeat doses of PC945
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">April 27, 2018</completion_date>
  <primary_completion_date type="Actual">April 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Assessment of number of adverse events reported by subjects following dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG assessment</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Change from pre-dose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs assessment (blood pressure and heart rate - measured together)</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Change for pre-dose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory assessments (blood and urine samples - measured together)</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Change from pre-dose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry assessment (FEV1 &amp; FVC - measured together)</measure>
    <time_frame>Cohort 1 - 12 weeks; Cohort 2 - 7 weeks; Cohort 3 - 6 weeks</time_frame>
    <description>Change from pre-dose values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration data of PC945</measure>
    <time_frame>Cohort 1 (4 treatment periods) &amp; Cohort 3 (1 treatment period) Day1 = 8 samples; Day2 = 2 samples; Day3 = 1 sample; F/U = 1 sample. Cohort 2 - Days1&amp;7 = 10 samples; Days2,5,6 = 1 sample; Day8 = 2 samples; Day9 = 1 sample; F/U = 1 sample</time_frame>
    <description>Blood levels of PC945 measured after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry assessment (FEV1)</measure>
    <time_frame>Cohort 3 only - Day 1, 8 hours</time_frame>
    <description>Observed drops in FEV1 assessment after dosing patients with mild asthma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determination of exogenous fungal flora</measure>
    <time_frame>Cohort 1 (4 treatment periods) &amp; Cohort 3 (1 treatment period) Day1 = 1 sample; Day3 = 1 sample. Cohort 2, Day 1 = 1 sample; Day 9 = 1 sample</time_frame>
    <description>Assessment of fungal flora found in mouth and throat after dosing</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Single dose - healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat dose - healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose - asthmatic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PC945 - single doses</intervention_name>
    <description>Safety and tolerability of single doses</description>
    <arm_group_label>Single dose - healthy volunteers</arm_group_label>
    <arm_group_label>Single dose - asthmatic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - single doses</intervention_name>
    <description>Safety and tolerability of single doses</description>
    <arm_group_label>Single dose - healthy volunteers</arm_group_label>
    <arm_group_label>Single dose - asthmatic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PC945 - repeat doses</intervention_name>
    <description>Safety and tolerability of repeat doses</description>
    <arm_group_label>Repeat dose - healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - repeat doses</intervention_name>
    <description>Safety and tolerability of repeat doses</description>
    <arm_group_label>Repeat dose - healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects (Cohorts 1, 2 &amp; 3)

          -  Male or female, aged between 18 and 65 years inclusive (at the time of consent) who
             fit one of the following criteria: Women of childbearing potential who are willing and
             able to use required contraception from screening until 30 days after receipt of the
             final dose; Women of non-childbearing potential defined as being amenorrhoeic or have
             been permanently sterilised; Men who are willing and able to use required
             contraception from the time of the first dose, until 90 days after receipt of the
             final dose of study medication.

          -  Females with a negative pregnancy test at screening and at Day -1.

          -  Willing and able to adhere to the restrictions and prohibitions required by this
             protocol.

          -  Signed informed consent form.

          -  Body weight ≥ 50 kg and body mass index (BMI) within the range 18 — 30 kg/m2
             (inclusive).

          -  Average QTcF &lt;450 msec at screening and pre-dose.

          -  Vital signs assessments within normal ranges

        Healthy Subjects (Cohorts 1 and 2)

          -  Healthy as determined by a physician based on a full medical examination.

          -  Spirometry readings (FEV1 and FVC) to be ≥ 80% of predicted value and FEV1/FVC ratio &gt;
             0.7 at screening.

        Subjects with Asthma (Cohort 3)

          -  Diagnosis of asthma.

          -  Positive result to methacholine challenge at the screening visit.

          -  FEV1 &gt;60% of predicted normal value at screening.

          -  Stable asthma based on physician assessment at screening, with no changes of therapy
             in the 12 weeks prior to screening and no hospitalization or visit to accident and
             emergency for asthma in the 12 months prior to screening

          -  Otherwise healthy on the basis of a full medical examination at screening

        Exclusion Criteria:

        All subjects (Cohorts 1, 2 &amp; 3)

          -  Any acute illness.

          -  Upper or lower respiratory tract infection within 4 weeks of the screening visit or
             randomisation.

          -  Use of prescription medications within 14 days of the Screening visit.

          -  Taking over the counter (OTC) medications other than vitamins or multivitamins, within
             14 days prior to Screening.

          -  History of regular alcohol consumption within 6 months of the study with average
             weekly intake of &gt;21 units for males, or &gt;14 units for females.

          -  History of drug or alcohol abuse within the previous 5 years.

          -  Smoker (regular or irregular), or has smoked or used nicotine-containing products
             (including e-cigarettes) within the 6 months prior to screening or has a smoking
             history of ≥ 10 pack years.

          -  Positive test for HIV-1 &amp; -2 antibodies at screening.

          -  Positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result
             at screening.

          -  Positive test for alcohol, smoking or drugs of abuse at screening or Day -1.

          -  Received an experimental drug or used an experimental medical device within last 3
             months.

          -  Allergy to any of the active or inactive ingredients in the study medication.

          -  Donation of blood in excess of 500 mL within a 3 month period prior to dosing, or if
             study participation would result in blood loss in excess of 500 mL in a 3 month
             period.

          -  Mentally or legally incapacitated.

          -  An employee of the Sponsor or contract research organisation (CRO), or a relative of
             an employee of the Sponsor or CRO.

          -  Unable or unwilling to undergo multiple venepuncture procedures or poor access to
             veins suitable for cannulation.

          -  Pregnant or lactating female

        Healthy subjects (Cohorts 1 and 2)

          -  Any chronic illness or clinically relevant abnormality identified on the screening
             medical assessment, laboratory tests or ECG.

        Subjects with asthma (Cohort 3)

          -  Had an episode of life-threatening asthma.

          -  Presence of clinically significant diseases other than asthma, hyper-responsive
             airways, seasonal allergic rhinitis or atopic diseases.

          -  Experienced an acute asthma exacerbation in the 12 months prior to screening requiring
             hospitalisation or accident and emergency treatment or management with systemic or
             injectable steroids.

          -  Uncontrolled, or moderate to severe asthma based on PI assessment and/or use of
             prohibited medications, or has required treatment with these therapies in the previous
             12 weeks.

          -  History or presence of any known conditions contraindicated for methacholine
             challenge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muna Albayaty, MBChB, FFPM, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>cro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel EPCU</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspergillus species</keyword>
  <keyword>Filamentous fungi</keyword>
  <keyword>14-alpha Demethylase Inhibitors</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Aspergillosis</keyword>
  <keyword>Allergic Bronchopulmonary</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

